ASDS Revenue first quarter 2019 Y/Y Growth Comment
Doughertys Pharmacy, Inc. reported decline in Revenue in the first quarter 2019 by -17.9% to $ 7.77 millions, from the same quarter in 2018. The contraction in the first quarter 2019 Doughertys Pharmacy, Inc.'s Revenue compares unfavorably to the Company's average Revenue fall of -13.33%.
Looking into first quarter 2019 results within Pharmacy Services & Retail Drugstore industry 18 other companies have achieved higher Revenue growth. While Doughertys Pharmacy, Inc.' s Revenue fall of -17.9% ranks overall at the positon no. 3517 in the first quarter 2019.
Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019
Doughertys Pharmacy,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
-1.07 %
-4.3 %
-10.38 %
(Dec 31 2018)
ASDS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2019 Doughertys Pharmacy, Inc. disclosed drop in Revenue from the fourth quarter by -10.42% to $ 7.77 millions, from $ 8.67 millions achived in the previous reporting period.
But that's not important problem, as Doughertys Pharmacy,'s Revenue generally seem to plunge in this quarter.
Within Pharmacy Services & Retail Drugstore industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Doughertys Pharmacy,'s Revenue growth quarter on quarter, overall rank is 2804.
In the I. Quarter 2019 Doughertys Pharmacy, Inc. disclosed drop in Revenue from the fourth quarter by -10.42% to $ 7.77 millions, from $ 8.67 millions achived in the previous reporting period.
But that's not important problem, as Doughertys Pharmacy,'s Revenue generally seem to plunge in this quarter.
Within Pharmacy Services & Retail Drugstore industry 52 other companies have achieved higher Revenue quarter on quarter growth. While Doughertys Pharmacy,'s Revenue growth quarter on quarter, overall rank is 2804.
Doughertys Pharmacy,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Mar 31 2019)
12 Months Ending (Dec 31 2018)
12 Months Ending (Sep 30 2018)
12 Months Ending (Jun 30 2018)
12 Months Ending (Mar 31 2018)
Cumulative Revenue 12 Months Ending
$ 34.36
$ 36.05
$ 37.38
$ 38.57
$ 9.46
Y / Y Revenue Growth (TTM)
-13.25 %
-10.35 %
-8.16 %
-7.63 %
-
Year on Year Revenue Growth Overall
Ranking
# 107
# 0
# 0
# 0
# 0
Seqeuential Revenue Change (TTM)
-4.68 %
-3.57 %
-3.07 %
-2.63 %
-
Seq. Revenue Growth (TTM) Overall
Ranking
# 3276
# 0
# 0
# 3030
# 0
Cumulative Revenue growth Comment
Doughertys Pharmacy,'s cumulative 12 months Revenue continue to fall, but on the faster rate at -13.25% year on year, at Mar 31 2019 compare to the -10.35% decrease at Dec 31 2018. If the Doughertys Pharmacy,'s fiscal year would end at Mar 31 2019, annual Revenue would be $34 millions.
Within the Retail sector 21 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 107.
Doughertys Pharmacy,'s cumulative 12 months Revenue continue to fall, but on the faster rate at -13.25% year on year, at Mar 31 2019 compare to the -10.35% decrease at Dec 31 2018. If the Doughertys Pharmacy,'s fiscal year would end at Mar 31 2019, annual Revenue would be $34 millions.
Within the Retail sector 21 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 107.
About Doughertys Pharmacy, Revenue Growth Rates (ASDS), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
